Form 4: Castle Biosciences COO Kristen Oelschlager Executes Stock Sale Under 10b5-1 Plan

Kristen Oelschlager, Chief Operating Officer of Castle Biosciences, sold 2,793 shares of common stock at a weighted-average price of $22.063 per share on July 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 29, 2024, Kristen Oelschlager, the Chief Operating Officer of Castle Biosciences, sold 2,793 shares of the company's common stock.
• The sale was executed at a weighted-average price of $22.063 per share.
• The transactions occurred in multiple trades with prices ranging from $22.02 to $22.12.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 15, 2024.
• Following the transaction, Oelschlager directly owns 145,825 shares of Castle Biosciences common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports an insider stock sale under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It is important to note that the sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which allows corporate insiders to sell company stock without being accused of trading on non-public information.

Stakeholder Impact

• The stock sale by a key executive could create uncertainty among shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates